Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last561 to 580 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Dalcetrapib (RO4607381) vs Placebo: Composite Endpoint:All Cause Mortality | 226 of 7,938 229 of 7,933 | -0.0 points -0.6 to 0.5 | 15,871 | NCT00658515 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome |
| Dalcetrapib (RO4607381) vs Placebo: serious adverse events | 1,688 of 7,938 1,692 of 7,933 | -0.1 points -1.3 to 1.2 | 15,871 | NCT00658515 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome |
| Cases vs Controls: Number of New Onset Skin Cancers in the Non-white Ethnicity Subgroup | 9 of 3,179 66 of 12,663 | -0.2 points -0.4 to 0.0 | 15,842 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Darapladib vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Non-fatal Stroke During the Time Period for Follow-up of CV Events | 926 of 7,924 962 of 7,904 | -0.5 points -1.5 to 0.5 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With First Occurrence of MI (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events | 361 of 7,924 405 of 7,904 | -0.6 points -1.2 to 0.1 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With All-cause Mortality During the Time Period for Vital Status | 582 of 7,924 577 of 7,904 | 0.0 points -0.8 to 0.9 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events (Coronary Heart Disease [CHD] Death, Non-fatal MI, or Urgent Coronary Revascularization [CR] for MI) During the Time Period for Follow-up (FU) of CV Events | 737 of 7,924 814 of 7,904 | -1.0 points -1.9 to -0.1 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events | 769 of 7,924 819 of 7,904 | -0.7 points -1.6 to 0.3 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With CV Death During the Time Period for Follow-up of CV Events | 359 of 7,924 373 of 7,904 | -0.2 points -0.8 to 0.5 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events | 154 of 7,924 152 of 7,904 | 0.0 points -0.4 to 0.5 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: deaths from any cause | 582 of 7,924 577 of 7,904 | 0.0 points -0.8 to 0.9 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During Time Period for FU of CV Events | 1,159 of 7,924 1,269 of 7,904 | -1.4 points -2.6 to -0.3 | 15,828 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| Darapladib vs Placebo: serious adverse events | 3,369 of 7,912 3,448 of 7,890 | -1.1 points -2.7 to 0.4 | 15,802 | NCT00799903 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| AAC Only vs AAC + TMCP: Number of Patients With Documentation of Brief Advice | 7,086 of 9,145 5,579 of 6,641 | -6.5 points -7.7 to -5.3 | 15,786 | NCT02764385 Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals |
| IBD Cases vs Matched Controls (Reference Group): Stream 1: Relative Risk of Any Mental Health Condition | 299 of 3,423 811 of 12,256 | 2.1 points 1.1 to 3.2 | 15,679 | NCT05206734 Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health |
| Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 3 | 5 of 7,707 3 of 7,805 | 0.0 points -0.1 to 0.1 | 15,512 | NCT03090191 Clostridium Difficile Vaccine Efficacy Trial |
| Omega-3 vs Placebo Omega-3: Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only) | 83 of 7,740 99 of 7,740 | -0.2 points -0.6 to 0.1 | 15,480 | NCT00135226 ASCEND: A Study of Cardiovascular Events iN Diabetes |
| Aspirin vs Placebo Aspirin: Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only) | 87 of 7,740 82 of 7,740 | 0.1 points -0.3 to 0.4 | 15,480 | NCT00135226 ASCEND: A Study of Cardiovascular Events iN Diabetes |
| Aspirin vs Placebo Aspirin: Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only) | 314 of 7,740 245 of 7,740 | 0.9 points 0.3 to 1.5 | 15,480 | NCT00135226 ASCEND: A Study of Cardiovascular Events iN Diabetes |
| Aspirin vs Placebo Aspirin: Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only) | 157 of 7,740 158 of 7,740 | -0.0 points -0.5 to 0.4 | 15,480 | NCT00135226 ASCEND: A Study of Cardiovascular Events iN Diabetes |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=29
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00658515-475d3899",
"title": "Dalcetrapib (RO4607381) vs Placebo: Composite Endpoint:All Cause Mortality",
"summary": "226 of 7938 against 229 of 7933; risk difference -0.0 points, 95% interval -0.6 to 0.5; NCT00658515, A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome",
"record": "/library/comparisons/NCT00658515-475d3899",
"nct_id": "NCT00658515",
"kind": "outcome",
"participants": 15871,
"risk_difference": {
"value": -0.0003961115892589587,
"lower": -0.005608294176255342,
"upper": 0.004813888193854889
},
"group_1": "226 of 7,938",
"group_2": "229 of 7,933",
"difference": "-0.0 points",
"interval": "-0.6 to 0.5",
"trial_title": "A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome"
},
{
"id": "NCT00658515-sae",
"title": "Dalcetrapib (RO4607381) vs Placebo: serious adverse events",
"summary": "1688 of 7938 against 1692 of 7933; risk difference -0.1 points, 95% interval -1.3 to 1.2; NCT00658515, A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome",
"record": "/library/comparisons/NCT00658515-sae",
"nct_id": "NCT00658515",
"kind": "serious-adverse-events",
"participants": 15871,
"risk_difference": {
"value": -0.0006382503606276457,
"lower": -0.013376982033315284,
"upper": 0.01210051797157327
},
"group_1": "1,688 of 7,938",
"group_2": "1,692 of 7,933",
"difference": "-0.1 points",
"interval": "-1.3 to 1.2",
"trial_title": "A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=30",
"request_id": "YJJjCjUPqGwb19bC"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant